Topics
March 2014 | Business Of Retina
The Use of Modifier Code -25 for Medicare and Medicaid Billing
Trexler M. Topping, MD
May 8, 2026
Drug Farm Presents Phase 1b DF-003 Data in ROSAH Syndrome at ARVO
Opus Genetics Reports Vision Restoration Data Across Multiple Gene Therapy Programs
May 7, 2026
Oculis Secures FDA SPA Agreement for PIONEER-1 Phase 3 Trial of Privosegtor in Optic Neuritis
May 6, 2026
Neuvasq Highlights Data for Targeting Antibodies for Blood Retina Barrier Restoration at ARVO
April 2026 Insert
Editorially independent supported by Abbvie and Regenxbio
April 2026 Supplement
Editorially independent content supported with advertising by EyePoint
Free Print Subscription
Email Newsletter
Conference Calendar
